1. Funding support may be provided to optimize the supply of application scenario resources in the area, with a maximum of CNY 100 million to focus on 10 or above high-level new-generation information technology application demonstration projects each year.

2. An annual funding support of CNY 100 million (for three consecutive years) may be granted for scientific and technological research to support the settlement and development of national laboratories, national technology innovation centers, national industrial innovation centers, and national manufacturing innovation centers in the 5G field in this area.

3. Up to CNY 100 million in innovation funding may be granted to leading enterprises that drive forward the development of industrial clusters with a total output value  CNY 100 billion.

4. A maximum of CNY 50 million in financial support may be granted to eligible enterprises that carry out research and development of engines, solid-state batteries, lightweight materials, and "bottleneck" technologies for battery, motor, and electric control systems, advance the R&D of products such as high-precision sensors, high-definition maps, chips suitable for automotive electronic components, and intelligent operating systems, and explore the R&D of advanced technologies for automobiles such as air compressors and membrane electrodes.

5. A maximum of CNY 100 million in financial support may be granted for the residence of national laboratories and national platform centers as well as new platforms that make breakthroughs in the R&D of key generic automobile technologies such as new electrical and electronic architectures for battery, motor and electric control technologies, fusion and perception of multi-source sensing information, new intelligent terminals, and fuel cells.

6. Conditional industrialization is encouraged for autonomous driving technology-related R&D projects that reach L4 or above. Commercialization of research results is encouraged for  new technologies such as fuel cells, vehicle-carried communication, computing, and sensing chips, etc. that have been certified for mass production conditions by national ministries, commissions and professional institutions. A maximum of CNY 100 million in financial support may be granted for enterprises that commercialize their initial batch of research results.

7. A maximum of CNY 20 million in financial support may be granted to enterprises that undertake national and municipal science and technology programs and projects and initiate clinical phase I, II, and III research projects in the fields of brand-name small molecule drugs, new antibody drugs, new vaccines, cell therapy, innovative formulations, gene therapy, high-end medical devices, modern Chinese medicine, etc..

8. Financial support may be granted to enterprises in the area that undertake commercialization of high-quality projects related to the "three science cities" (Zhongguancun Science City, Huairou Science City, and Future Science Park) or national projects, with a maximum of CNY 50 million for each innovative product that are successfully commercialized and approved for production.

9. Innovative drugs that have obtained national new drug registration approval (combined calculation of different dosage forms) in Beijing will be covered by the support for major industrialization projects regarding high-end, precision and sophisticated technologies in the Zhongguancun National Innovation Demonstration Zone. Innovative drugs that have completed Phase II clinical trials and the first generic drugs that have passed the evaluation of consistency of quality and efficacy in China will also be covered by such support on a merit basis. A financial support of not more than 30 percent of the total project investment, up to an annual maximum of CNY 10 million, may be granted (No duplicated support for the same innovative drug).

10. Innovative drugs in the clinical trial stage may be covered on a merit basis by the support for major industrialization projects regarding high-end, precision and sophisticated technologies in the Zhongguancun National Innovation Demonstration Zone. A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

11. Innovative medical apparatuses and instruments that have been approved by the national special review process for industrialization in the Zhongguancun National Innovation Demonstration Zone may be covered on a merit basis by the support for industrialization projects regarding high-end, precision and sophisticated technologies in the zone. A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

12. Enterprises with proprietary intellectual property rights and holding the second and third-class medical device registration certificates and production licenses in Beijing may be covered on a merit basis by the support for major industrialization regarding high-end, precision and sophisticated technologies in the Zhongguancun National Innovation Demonstration Zone. A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

13. Innovation entities in the Zhongguancun Demonstration Zone that build professional R&D, production, and service platforms in line with international standards, such as service platforms for biological medicine pilot tests over 1,000 liters in scale, high-end preparations platforms, medical contracted R&D institutions, contract customized R&D production service organizations, OEM or ODM production service platforms, medical device engineering platforms, and industrialization technical personnel training platforms, may be covered on a merit basis by the support for collaborative innovation platforms regarding high-end, precision and sophisticated industries in the Zhongguancun National Innovation Demonstration Zone. A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

14. The construction of biomedical imports and exports service platforms in Zhongguancun and platforms for new drug evaluation, laboratory animals, testing, and inspection may be covered on a merit basis by the support for collaborative innovation platforms regarding high-end, precision and sophisticated industries in the Zhongguancun National Innovation Demonstration Zone. A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

15. High-level medical institutions, colleges, universities, and research institutes in Beijing are encouraged and supported to join enterprises in the Zhongguancun Demonstration Zone and build centers for the commercialization of medical achievements. Eligible projects with significant achievements will be identified as Zhongguancun centers for medical achievement commercialization and may be covered by the support for collaborative innovation platforms regarding high-end, precision and sophisticated industries in the Zhongguancun National Innovation Demonstration Zone. A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

16. All kinds of innovation entities are encouraged and supported to plan and construct hard & core technology incubators for pharmaceuticals along with medical apparatuses and instruments in key parks, colleges, universities, research institutes and medical institution clusters. Such incubators with outstanding service performance may be covered on a merit basis by the support for hard & core technology incubators in Zhongguancun.  A financial support of not more than 30 percent of the total project investment may be granted, up to an annual maximum of CNY 10 million.

17. Global pharmaceutical and medical device leaders are encouraged and supported to build regional headquarters and R&D centers in the Zhongguancun National Innovation Demonstration Zone. A financial support equivalent to 30 percent of the actual expenses incurred may be granted, up to a maximum of CNY 5 millionlion annually for each individual enterprise. 

18. Drugs and medical devices newly certified by authoritative international institutions such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) may receive a maximal one-time financial support of CNY 3 million, not more than 30 percent of the actual expenses.

19. Intelligent manufacturing system solution providers who provide consulting, diagnosis, and project implementation services may receive a certain percentage of up to CNY 20 million in financial support.

20. Enterprises, institutions of higher-learning, and research institutes may receive a financial support of up to CNY 100 million for the building of officially recognized national manufacturing innovation centers or internationally renowned innovation centers in the development zone.

21. A science and technology innovation fund will be set up for with an annual investment of CNY 500 million to guide social capitals to invest in and support technology-based or innovation-based enterprises in the development zone, and to attract superior enterprises to settle and develop in the zone.

22. Leading enterprises are supported in building key resource-sharing carriers for industries. Resource-based services are open to small and medium-sized enterprises, such as supply chain collaboration, capital financing, brand connection, big data application, human resources training, and R&D of patents. A certain amount of financial support may be provided, with a maximum of CNY 3 million for a single carrier.

23. Support is provided for the establishment of regional-level cloud platforms for "Internet plus" services that are designed for the online and offline provision of professional services such as strategic decision making, process control, standard accounting, corporate governance, matching of investment and financing, and acquisition financing. The amount of such support may reach up to CNY 4 million.

24. Newly-recognized state-level and city-level enterprises for their specialization, expertise, uniqueness, and novelty, along with single-item champion manufacturing enterprises, may be granted a reward of no more than CNY 300,000 and CNY 100,000 respectively. The difference will be compensated for upgrading of city-level enterprises to national-level ones. Targeted innovation service vouchers will be first issued to enterprises in the carriers that have received science and technology awards and qualifications according to their development stages, with a total value of not more than CNY 3 million.

25. Enterprises that have acquired listed companies, NEEQ-quoted enterprises, and high-tech enterprises above the designated scale and relocated the entities into the area may receive incentives of up to RMB 3 million, RMB 500,000 and RMB 500,000 respectively, equivalent to 5 per-mille of the acquisition transaction amount.